Comparison between a new platelet count drop method PL-11, light transmission aggregometry, VerifyNow aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals

Platelets

Volumn 26, Issue 1, 2015, Pages 25-30

  Guan, Jie ^a   Cong, Yulong ^a   Ren, Junwei ^b   Zhu, Yuan ^a   Li, Li ^a   Deng, Xinli ^a   Bai, Jie ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beijing northern Hospital   (China)

Author keywords

Aspirin; Light transmittance aggregometry; PL 11; Platelet count drop method; Thromboelastography; VerifyNow

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG MONITORING; HUMAN; INTERMETHOD COMPARISON; LIGHT TRANSMISSION AGGREGOMETRY; MALE; NORMAL HUMAN; PL 11 ASSAY; POINT OF CARE TESTING; PRIORITY JOURNAL; SHORT COURSE THERAPY; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD CLOTTING PARAMETERS; DEVICES; DRUG EFFECTS; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; YOUNG ADULT;

ADULT; ASPIRIN; BLOOD PLATELETS; HEALTHY VOLUNTEERS; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; ROC CURVE; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 84921535078     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.865835     Document Type: Article

References (30)

1. Harrison P. Advances in the monitoring of anti-P2Y12 therapy. Platelets 2012;23:510-525.
2. Lordkipanidze M. Advances in monitoring of aspirin therapy. Platelets 2012;23:526-536.
3. Sambu N, Curzen N. Monitoring the effectiveness of antiplatelet therapy: Opportunities and limitations. Br J Clin Pharmacol 2011; 72:683-696.
4. Gurbel PABK, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826.
5. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-2425.
6. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317.
7. Madsen EH, Schmidt EB, Maurer-Spurej E, Kristensen SR. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 2008;19:335-341.
8. Cohen MG, Rossi JS, Garbarino J, Bowling R, Motsinger-Reif AA, Schuler C, Dupont AG, Gabriel D. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: Beyond aspirin and clopidogrel. Thromb Res 2011;128: 335-340.
9. Kovács EG, Katona E, Bereczky Z, Homoródi N, Balogh L, Tóth E, Péterfy H, Kiss RG, Edes I, Muszbek L. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; The lack of aspirin resistance among healthy individuals. Thromb Res 2011;131:320-324.
10. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4:813-819.
11. Schrör K, Huber K, Hohlfeld T. Functional testing methods for the antiplatelet effects of aspirin. Biomark Med 2011;5:31-42.
12. Coleman JL, Alberts MJ. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Am J Cardiol 2006;98:838-841.
13. Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost 2012;10:521-528.
14. Spectre G, Mosseri M, Abdelrahman NM, Briskin E, Bulut A, Loncar S, Varon D, Alcalai R. Clinical and prognostic implications of the initial response to aspirin in patients with acute coronary syndrome. Am J Cardiol 2011;108:112-118.
15. Xu ZH, Jiao JR, Yang R, Luo BY, Wang XF, Wu F. Aspirin resistance: Clinical significance and genetic polymorphism. J Int Med Res 2012;40:282-292.
16. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
17. Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45: 1748-1752.
18. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005;145:309-315.
19. 2. Thromb Haemost 2009;102:404-411.
20. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006;4:813-819.
21. Lordkipanidzé M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry. Thromb Res 2009;124:418-422.
22. van Werkum JW, Kleibeuker M, Postma S, Bouman HJ, Elsenberg EH, ten Berg JM, Hackeng CM. A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol 2010;140: 123-126.
23. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97: 350-355.
24. Heptinstall S, Johnson A, Glenn JR, White AE. Adenine nucleotide metabolism in human blood-Important roles for leukocytes and erythrocytes. J Thromb Haemost 2005;3:2331-2339.
25. Hussein HM, Emiru T, Georgiadis AL, Qureshi AI. Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures. AJNR Am J Neuroradiol 2013;34:700-706.
26. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation 1998;98:1616-1621.
27. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-1123.
28. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM. High on-aspirin platelet reactivity as measured with aggregation based, COX-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010;8:2140-2148.
29. Sambu N, Hobson A, Curzen N. "Short" thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: Validation and reproducibility. Platelets 2011;22:210-216.
30. Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010;56:839-847.